Proteomic insights into chronic anthracycline cardiotoxicity

Journal of Molecular and Cellular Cardiology

Volumn 50, Issue 5, 2011, Pages 849-862

  Štěrba, Martin ^a   Popelová, Olga ^a   Lenčo, Juraj ^b   Fučíková, Alena ^b   Brčáková, Eva ^a,c   Mazurová, Yvona ^a   Jirkovskỳ, Eduard ^a   Šimůnek, Tomáš ^c   Adamcová, Michaela ^a   Mičuda, Stanislav ^a   Stulík, Jiří ^b   Geršl, Vladimír ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF DEFENCE   (Czech Republic)

^c Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

Chronic anthracycline cardiotoxicity; Complex I; Desmin; Energy channeling; Proteomics; Superoxide dismutase

Indexed keywords

COLLAGEN TYPE 6; DAUNORUBICIN; DESMIN; LAMININ RECEPTOR; MYOSIN LIGHT CHAIN; SUPEROXIDE DISMUTASE; TROPONIN I; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BASEMENT MEMBRANE; CARDIOTOXICITY; CONTROLLED STUDY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HEART CATHETERIZATION; HEART FAILURE; HEART LEFT VENTRICLE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANIMALS; ANTHRACYCLINES; BLOTTING, WESTERN; DAUNORUBICIN; ECHOCARDIOGRAPHY; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; EXTRACELLULAR MATRIX; HEART FAILURE; HEART VENTRICLES; IMMUNOHISTOCHEMISTRY; MALONDIALDEHYDE; MITOCHONDRIAL PROTEINS; MYOCARDIUM; PROTEOMICS; RABBITS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TROPONIN I; VIMENTIN;

ORYCTOLAGUS CUNICULUS;

EID: 79953704166     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.01.018     Document Type: Article

References (52)

1. Ewer M.S., Yeh E. Cancer and the heart 2006, BC Decker Inc., Hamilton, Ont.
2. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev Jun 2004, 56(2):185-229.
3. Gianni L., Herman E.H., Lipshultz S.E., Minotti G., Sarvazyan N., Sawyer D.B. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol Aug 1 2008, 26(22):3777-3784.
4. Simunek T., Sterba M., Popelova O., Adamcova M., Hrdina R., Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep Jan-Feb 2009, 61(1):154-171.
5. Popelova O., Sterba M., Simunek T., Mazurova Y., Guncova I., Hroch M., et al. Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo. J Pharmacol Exp Ther Jul 2008, 326(1):259-269.
6. Sterba M., Popelova O., Simunek T., Mazurova Y., Potacova A., Adamcova M., et al. Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity. J Pharmacol Exp Ther Dec 2006, 319(3):1336-1347.
7. Sawyer D.B., Peng X., Chen B., Pentassuglia L., Lim C.C. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?. Prog Cardiovasc Dis Sep-Oct 2010, 53(2):105-113.
8. Tokarska-Schlattner M., Zaugg M., Zuppinger C., Wallimann T., Schlattner U. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol Sep 2006, 41(3):389-405.
9. Wallace K.B. Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovasc Toxicol 2007, 7(2):101-107.
10. Lebrecht D., Walker U.A. Role of mtDNA lesions in anthracycline cardiotoxicity. Cardiovasc Toxicol 2007, 7(2):108-113.
11. Simunek T., Klimtova I., Kaplanova J., Mazurova Y., Adamcova M., Sterba M., et al. Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents. Eur J Heart Fail Jun 2004, 6(4):377-387.
12. Powell S.R., Davies K.J., Divald A. Optimal determination of heart tissue 26S-proteasome activity requires maximal stimulating ATP concentrations. J Mol Cell Cardiol Jan 2007, 42(1):265-269.
13. Herman E.H., Ferrans V.J. Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity. Semin Oncol Aug 1998, 25(4 Suppl 10):15-21.
14. Agnetti G., Kaludercic N., Kane L.A., Elliott S.T., Guo Y., Chakir K., et al. Modulation of mitochondrial proteome and improved mitochondrial function by biventricular pacing of dyssynchronous failing hearts. Circ Cardiovasc Genet Feb 1 2010, 3(1):78-87.
15. Vondriska T.M., Ping P. Functional proteomics to study protection of the ischaemic myocardium. Expert Opin Ther Targets Oct 2002, 6(5):563-570.
16. White M.Y., Tchen A.S., McCarron H.C., Hambly B.D., Jeremy R.W., Cordwell S.J. Proteomics of ischemia and reperfusion injuries in rabbit myocardium with and without intervention by an oxygen-free radical scavenger. Proteomics Dec 2006, 6(23):6221-6233.
17. Almeida T., Duarte M., Melo A.M., Videira A. The 24-kDa iron-sulphur subunit of complex I is required for enzyme activity. Eur J Biochem Oct 1 1999, 265(1):86-93.
18. Yen H.C., Oberley T.D., Gairola C.G., Szweda L.I., St Clair D.K. Manganese superoxide dismutase protects mitochondrial complex I against adriamycin-induced cardiomyopathy in transgenic mice. Arch Biochem Biophys Feb 1 1999, 362(1):59-66.
19. Ohkura K., Lee J.D., Shimizu H., Nakano A., Uzui H., Horikoshi M., et al. Mitochondrials complex I activity is reduced in latent adriamycin-induced cardiomyopathy of rat. Mol Cell Biochem Jun 2003, 248(1-2):203-208.
20. Goormaghtigh E., Chatelain P., Caspers J., Ruysschaert J.M. Evidence of a complex between adriamycin derivatives and cardiolipin: possible role in cardiotoxicity. Biochem Pharmacol Nov 1 1980, 29(21):3003-3010.
21. Davies K.J., Doroshow J.H. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J Biol Chem Mar 5 1986, 261(7):3060-3067.
22. Li T., Singal P.K. Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol. Circulation Oct 24 2000, 102(17):2105-2110.
23. Weisleder N., Takeshima H., Ma J. Mitsugumin 53 (MG53) facilitates vesicle trafficking in striated muscle to contribute to cell membrane repair. Commun Integr Biol. May 2009, 2(3):225-226.
24. Lenco J., Sterba M., Mazurova Y., Popelova O., Brychta M., Stulik J., et al. Proteomic analysis in the study of anthracycline-induced cardiomyopathy. Mol Cell Proteomics Oct 2006, 5(10):S83.
25. Oliveira P.J., Wallace K.B. Depletion of adenine nucleotide translocator protein in heart mitochondria from doxorubicin-treated rats-relevance for mitochondrial dysfunction. Toxicology Mar 15 2006, 220(2-3):160-168.
26. Tokarska-Schlattner M., Wallimann T., Schlattner U. Multiple interference of anthracyclines with mitochondrial creatine kinases: preferential damage of the cardiac isoenzyme and its implications for drug cardiotoxicity. Mol Pharmacol Mar 2002, 61(3):516-523.
27. Garry D.J., Meeson A., Yan Z., Williams R.S. Life without myoglobin. Cell Mol Life Sci Jun 2000, 57(6):896-898.
28. Schaap F.G., Binas B., Danneberg H., van der Vusse G.J., Glatz J.F. Impaired long-chain fatty acid utilization by cardiac myocytes isolated from mice lacking the heart-type fatty acid binding protein gene. Circ Res Aug 20 1999, 85(4):329-337.
29. Sayed-Ahmed M.M., Al-Shabanah O.A., Hafez M.M., Aleisa A.M., Al-Rejaie S.S. Inhibition of gene expression of heart fatty acid binding protein and organic cation/carnitine transporter in doxorubicin cardiomyopathic rat model. Eur J Pharmacol Aug 25 2010, 640(1-3):143-149.
30. Mannaerts G.P., Van Veldhoven P.P., Casteels M. Peroxisomal lipid degradation via beta- and alpha-oxidation in mammals. Cell Biochem Biophys 2000, 32:73-87. [Spring].
31. Chen Y., Daosukho C., Opii W.O., Turner D.M., Pierce W.M., Klein J.B., et al. Redox proteomic identification of oxidized cardiac proteins in adriamycin-treated mice. Free Radic Biol Med Nov 1 2006, 41(9):1470-1477.
32. Guertl B., Noehammer C., Hoefler G. Metabolic cardiomyopathies. Int J Exp Pathol Dec 2000, 81(6):349-372.
33. Capetanaki Y., Bloch R.J., Kouloumenta A., Mavroidis M., Psarras S. Muscle intermediate filaments and their links to membranes and membranous organelles. Exp Cell Res Jun 10 2007, 313(10):2063-2076.
34. Milner D.J., Mavroidis M., Weisleder N., Capetanaki Y. Desmin cytoskeleton linked to muscle mitochondrial distribution and respiratory function. J Cell Biol Sep 18 2000, 150(6):1283-1298.
35. Capetanaki Y. Desmin cytoskeleton: a potential regulator of muscle mitochondrial behavior and function. Trends Cardiovasc Med Nov 2002, 12(8):339-348.
36. Panagopoulou P., Davos C.H., Milner D.J., Varela E., Cameron J., Mann D.L., et al. Desmin mediates TNF-alpha-induced aggregate formation and intercalated disk reorganization in heart failure. J Cell Biol Jun 2 2008, 181(5):761-775.
37. Chen F., Chang R., Trivedi M., Capetanaki Y., Cryns V.L. Caspase proteolysis of desmin produces a dominant-negative inhibitor of intermediate filaments and promotes apoptosis. J Biol Chem Feb 28 2003, 278(9):6848-6853.
38. Williamson C.L., Dabkowski E.R., Dillmann W.H., Hollander J.M. Mitochondria protection from hypoxia/reoxygenation injury with mitochondria heat shock protein 70 overexpression. Am J Physiol Heart Circ Physiol Jan 2008, 294(1):H249-H256.
39. Massey A., Kiffin R., Cuervo A.M. Pathophysiology of chaperone-mediated autophagy. Int J Biochem Cell Biol Dec 2004, 36(12):2420-2434.
40. Severino A., Campioni M., Straino S., Salloum F.N., Schmidt N., Herbrand U., et al. Identification of protein disulfide isomerase as a cardiomyocyte survival factor in ischemic cardiomyopathy. J Am Coll Cardiol Sep 11 2007, 50(11):1029-1037.
41. Willis M.S., Schisler J.C., Portbury A.L., Patterson C. Build it up-Tear it down: protein quality control in the cardiac sarcomere. Cardiovasc Res Feb 15 2009, 81(3):439-448.
42. Fekete M.R., McBride W.H., Pajonk F. Anthracyclines, proteasome activity and multi-drug-resistance. BMC Cancer Sep 13 2005, 5.
43. Liu J.B., Zheng H.Q., Tang M.X., Ryu Y.C., Wang X.J. A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome. Am J Physiol Heart Circ Physiol Dec 2008, 295(6):H2541-H2550.
44. Lim C.C., Zuppinger C., Guo X., Kuster G.M., Helmes M., Eppenberger H.M., et al. Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem Feb 27 2004, 279(9):8290-8299.
45. Popelova O., Sterba M., Haskova P., Simunek T., Hroch M., Guncova I., et al. Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death. Br J Cancer Sep 1 2009, 101(5):792-802.
46. Rahman-Roblick R., Roblick U.J., Hellman U., Conrotto P., Liu T., Becker S., et al. p53 targets identified by protein expression profiling. Proc Natl Acad Sci USA Mar 27 2007, 104(13):5401-5406.
47. Torti S.V., Akimoto H., Lin K., Billingham M.E., Torti F.M. Selective inhibition of muscle gene expression by oxidative stress in cardiac cells. J Mol Cell Cardiol Jun 1998, 30(6):1173-1180.
48. Okamoto O., Fujiwara S. Dermatopontin, a novel player in the biology of the extracellular matrix. Connect Tissue Res 2006, 47(4):177-189.
49. Boyd J.H., Chau E.H., Tokunanga C., Bateman R.M., Haljan G., Davani E.Y., et al. Fibrinogen decreases cardiomyocyte contractility through an ICAM-1-dependent mechanism. Crit Care 2008, 12(1):R2.
50. Li T., Wang Y., Liu C., Hu Y., Wu M., Li J., et al. MyD88-dependent nuclear factor-kappaB activation is involved in fibrinogen-induced hypertrophic response of cardiomyocytes. J Hypertens May 2009, 27(5):1084-1093.
51. Lyu Y.L., Kerrigan J.E., Lin C.P., Azarova A.M., Tsai Y.C., Ban Y., et al. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res Sep 15 2007, 67(18):8839-8846.
52. Yi X., Bekeredjian R., DeFilippis N.J., Siddiquee Z., Fernandez E., Shohet R.V. Transcriptional analysis of doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol Mar 2006, 290(3):H1098-H1102.